Mavrilimumab

Status
Phase 2
Condition
COVID-19
Intervention Type
Intravenous (IV) Injection
Funder Type
Organization | University

Drug Details

Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor.

Study Purpose

The primary endpoint of this study is to assess the effects of a single IV dose of mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >